Functional characterization of two naturally occurring mutations in the human sodium-phosphate cotransporter type IIa.
Mutations in the gene encoding the human sodium-phosphate cotransporter (NPT2), causing reduced phosphate affinity and dominant-negative behavior, were described. We found no evidence of altered kinetics or dominant-negative effects. Thus, the mutations cannot account for the clinical phenotype.


BACKGROUND
Mutations in NPT22a, the gene encoding the sodium-phosphate cotransporter NaPi-IIa, were for the first time linked to human disease by Priè and colleagues. Two patients are described with renal phosphate wasting who were heterozygous for either the A48F or V147M mutation. Expressed in Xenopus oocytes, both mutants showed reduced phosphate affinity. Furthermore, coexpression of mutants with wildtype (WT) NaPi-IIa resulted in reduced cotransport function, explaining the mutants' dominant-negative effect in the patients. Intrigued by the implications of these findings on transporter kinetics, we decided to examine the transport characteristics of the two mutants in more detail.


METHODS
We recreated the two mutants, expressed them in Xenopus oocytes, and analyzed their kinetic behavior by two-electrode voltage clamp. We also performed coexpression experiments where we injected mRNA for WT and mutants containing an additional S462C mutation, enabling complete inhibition of cotransport function with cysteine-modifying reagents. Finally, we expressed WT and mutant NaPi-IIa as C-terminal fusions to green fluorescent protein (GFP) in opossum kidney (OK) cells.


CONCLUSIONS
We found in our oocyte expression experiments that P(i)-induced currents were reduced in both mutants, whereas P(i) and Na affinities and other transport characteristics were not affected. The amount of cotransport activity remaining after cysteine modification, corresponding to WT activity, was not affected by coexpression of either mutant. Finally, GFP-tagged WT and mutants were expressed at the apical membrane in OK cells, showing that both mutants are correctly targeted in a mammalian cell. In conclusion, our data from oocyte and OK cell expression studies suggest that the heterozygous A48F and V 147M mutations cannot explain the pathological phenotype observed by Priè and colleagues.
Virkki
Leila V
LV
Institute of Physiology, University of Zurich, Zurich, Switzerland.
Forster
Ian C
IC
Hernando
Nati
N
Biber
Jürg
J
Murer
Heini
H
D000818:Animals; D002460:Cell Line; D005260:Female; D006801:Humans; D007700:Kinetics; D008564:Membrane Potentials / Q000502:physiology; D009154:Mutation; D009865:Oocytes / Q000502:physiology; D009893:Opossums; D011994:Recombinant Proteins / Q000378:metabolism; D050608:Sodium-Phosphate Cotransporter Proteins; D050609:Sodium-Phosphate Cotransporter Proteins, Type I; D050611:Sodium-Phosphate Cotransporter Proteins, Type III; D050613:Sodium-Phosphate Cotransporter Proteins, Type IIa; D027981:Symporters / Q000235:genetics* / Q000502:physiology; D014162:Transfection; D014982:Xenopus laevis
D011994:Recombinant Proteins; C493548:SLC17A2 protein, human; C493554:SLC34A1 protein, human; D050608:Sodium-Phosphate Cotransporter Proteins; D050609:Sodium-Phosphate Cotransporter Proteins, Type I; D050611:Sodium-Phosphate Cotransporter Proteins, Type III; D050613:Sodium-Phosphate Cotransporter Proteins, Type IIa; D027981:Symporters